Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY: LLY )

207.41 USD +0.94 (+0.46%)
Streaming Delayed Price Updated: 10:51 AM EST, Mar 2, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
U.S. Government to Purchase Minimum of 100,000 Doses of Etesevimab and Bamlanivimab Neutralizing Antibody Therapy
From GlobeNewswire News Releases
Lilly announces additional doses of neutralizing antibody therapy purchased by U.S. government to treat COVID-19
The U.S. government has agreed to purchase a minimum of 100,000 doses of bamlanivimab (LY-CoV555) 700 mg and etesevimab (LY-CoV016) 1400 mg together, Eli Lilly and Company (NYSE: LLY) announced.... 
From PR Newswire
Welldoc and Lilly collaborate to integrate BlueStar® app capabilities into Lilly's connected insulin solutions
Welldoc, Inc., and Eli Lilly and Company (NYSE: LLY) announced today a collaboration and licensing agreement to integrate Welldoc's software into Lilly's connected insulin solutions, currently in... 
From PR Newswire
Lilly to Participate in Cowen Health Care Conference
Eli Lilly and Company (NYSE: LLY) will participate in the Cowen and Company 41st Annual Health Care Conference on Thursday, March 4, 2021. Daniel Skovronsky, M.D., Ph.D., Lilly's Chief Scientific... 
From PR Newswire
Lilly and Rigel Enter Strategic Collaboration to Develop RIPK1 Inhibitors for the Potential Treatment of Immunological and Neurodegenerative Diseases
- Lilly will obtain an exclusive worldwide license to Rigel's RIPK1 inhibitors, including Rigel's Phase 2-ready molecule R552, in all indications 
From PR Newswire
Tirzepatide significantly reduced A1C and body weight in people with type 2 diabetes in two phase 3 trials from Lilly's SURPASS program
In the 52-week SURPASS-3 study - the longest in the program to date - the highest dose of tirzepatide reduced A1C by 2.37 percent and body weight by 12.9 kg (28.4 lb., 13.9 percent) 
From PR Newswire
Kimberly H. Johnson Elected to Lilly Board of Directors
The board of directors of Eli Lilly and Company (NYSE: LLY) has elected Kimberly H. Johnson as a new member, effective February 16, 2021. As a member of Lilly's board, she will serve on both the... 
From PR Newswire
Lilly To Participate in SVB Leerink Global Healthcare Conference
Eli Lilly and Company (NYSE:LLY) will participate in the 10th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 24, 2021. Ilya Yuffa, Lilly senior vice president and president of... 
From PR Newswire
Thinking about trading options or stock in Coca-Cola, Eli Lilly, Baidu, Canopy Growth Corp, or Match Group?
InvestorsObserver issues critical PriceWatch Alerts for KO, LLY, BIDU, CGC, and MTCH. 
From PR Newswire
Etesevimab (JS016) Administered with Bamlanivimab Receives FDA Emergency Use Authorization for COVID-19
From GlobeNewswire News Releases
Lilly's bamlanivimab (LY-CoV555) administered with etesevimab (LY-CoV016) receives FDA emergency use authorization for COVID-19
- Bamlanivimab and etesevimab administered together authorized for treatment of recently diagnosed, mild to moderate COVID-19 in patients who are high risk for progression to severe COVID-19 
From PR Newswire
Lilly Appoints Anat Ashkenazi Chief Financial Officer
Eli Lilly and Company (NYSE: LLY) today announced the appointment of Anat Ashkenazi as senior vice president and chief financial officer. Ms. Ashkenazi, who most recently served in the role of senior... 
From PR Newswire
Lilly Announces Webcast to Provide Alzheimer's Disease Update at AD/PD Conference
Eli Lilly and Company (NYSE: LLY) will conduct a webcast on Monday, March 15, 2021 to provide an update on its Alzheimer's disease program and discuss results from the Phase 2 TRAILBLAZER-ALZ study for... 
From PR Newswire
Lilly to Participate in Guggenheim Healthcare Talks 2021 Oncology Day
Eli Lilly and Company (NYSE: LLY) will participate in the Guggenheim Healthcare Talks 2021 Oncology Day on Friday, February 12, 2021. Anne White, senior vice president and president, Lilly Oncology,... 
From PR Newswire
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small
Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic,... 
From PR Newswire
Lilly Partners with Area Health Systems to Help Enable Access to Important Antibody Infusion Therapies for COVID-19 Patients
Eli Lilly and Company (NYSE: LLY) has partnered with local health systems to launch dedicated infusion center locations serving central, northern, and now southern Indiana that are intended to provide... 
From PR Newswire
Should you invest in Dillard's, Inovio Pharmaceuticals, Eli Lilly, Nektar Therapeutics, or Carnival Corp?
InvestorsObserver issues critical PriceWatch Alerts for DDS, INO, LLY, NKTR, and CCL. 
From PR Newswire
Lilly Reports Strong Fourth-Quarter and Full-Year 2020 Financial Results
- Revenue in the fourth quarter of 2020 increased 22 percent, driven by volume growth of 24 percent. Excluding bamlanivimab revenue of $871 million, fourth-quarter 2020 revenue grew 7 percent. 
From PR Newswire
Lilly, Life for a Child and Beyond Type 1 advance partnership to improve diabetes care in resource-limited countries
Partnership expands access to care for children and young people with diabetes to approximately 150,000 in 65 countries 
From PR Newswire
Lilly and Asahi Kasei Pharma Announce License Agreement for Chronic Pain Drug Candidate
Eli Lilly and Company (NYSE: LLY) and Asahi Kasei Pharma Corporation today announced a license agreement whereby Lilly will acquire the exclusive rights for AK1780 from Asahi Kasei Pharma. AK1780 is an... 
From PR Newswire
Lilly, Vir Biotechnology and GSK Announce First Patient Dosed in Expanded BLAZE-4 Trial Evaluating Bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
From GlobeNewswire News Releases
Lilly, Vir Biotechnology and GSK announce first patient dosed in expanded BLAZE-4 trial evaluating bamlanivimab (LY-CoV555) with VIR-7831 (GSK4182136) for COVID-19
Eli Lilly and Company (NYSE: LLY), Vir Biotechnology, Inc. (NASDAQ: VIR) and GlaxoSmithKline plc (LSE/NYSE: GSK) today announced a collaboration to evaluate a combination of two COVID-19 therapies in... 
From PR Newswire
New data show treatment with etesevimab (JS016) and bamlanivimab together reduced risk of COVID-19 hospitalizations and death by 70 percent
From GlobeNewswire News Releases
Thinking about trading options or stock in Eli Lilly, Apple, Moderna, Workhorse Group, or iRobot?
InvestorsObserver issues critical PriceWatch Alerts for LLY, AAPL, MRNA, WKHS, and IRBT. 
From PR Newswire
New data show treatment with Lilly's neutralizing antibodies bamlanivimab (LY-CoV555) and etesevimab (LY-CoV016) together reduced risk of COVID-19 hospitalizations and death by 70 percent
- BLAZE-1 trial met primary endpoint and key secondary endpoints with high statistical significance 
From PR Newswire
Lilly Completes Acquisition of Prevail Therapeutics
Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery... 
From PR Newswire
Lilly's neutralizing antibody bamlanivimab (LY-CoV555) prevented COVID-19 at nursing homes in the BLAZE-2 trial, reducing risk by up to 80 percent for residents
Bamlanivimab (LY-CoV555) significantly reduced the risk of contracting symptomatic COVID-19 among residents and staff of long-term care facilities, Eli Lilly and Company (NYSE: LLY) announced. The... 
From PR Newswire
Thinking about trading options or stock in General Motors, Eli Lilly, CarMax, Micron Technology, or Roku?
InvestorsObserver issues critical PriceWatch Alerts for GM, LLY, KMX, MU, and ROKU. 
From PR Newswire
Lilly and Merus NV Announce Collaboration to Discover Novel T-Cell Re-Directing Bispecific Antibodies
Loxo Oncology at Lilly, a research and development group of Eli Lilly and Company (NYSE: LLY), and Merus N.V. (NASDAQ: MRUS), a clinical-stage oncology company developing multi-specific antibodies,... 
From PR Newswire
Lilly Confirms Date and Conference Call for Fourth-Quarter 2020 Financial Results Announcement
Eli Lilly and Company (NYSE: LLY) will announce its fourth-quarter and full-year 2020 financial results on Friday, January 29, 2021. Lilly will also conduct a conference call on that day with the... 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
89 90 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.